Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Belgium
/
Healthcare
/
Nyxoah
NYXH
Nyxoah
Minimally Invasive Devices Will Capture Expanding Sleep Market
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
17 Aug 25
Updated
21 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
€18.60
71.2% undervalued
intrinsic discount
21 Aug
€5.36
Loading
1Y
-28.5%
7D
-4.8%
Author's Valuation
€18.6
71.2% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
€18.6
71.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-233m
135m
2017
2019
2021
2023
2025
2027
2028
Revenue €135.2m
Earnings €5.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
52.93%
Medical Equipment revenue growth rate
0.43%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.99%
Calculation
€5.47m
Earnings '28
x
201.17x
PE Ratio '28
=
€1.10b
Market Cap '28
€1.10b
Market Cap '28
/
48.29m
No. shares '28
=
€22.78
Share Price '28
€22.78
Share Price '28
Discounted to 2025 @ 6.99% p.a.
=
€18.60
Fair Value '25